Cystic Fibrosis Foundation has issued the following clinical trial alerts in September.
September 7, 2021
Status: Enrolling
Description: This study is testing the safety and tolerability of nebulized BX004-A, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (PsA) to find the best dose.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 40% or greater
Number of Visits: 9
Length of Participation: 192 days
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT05010577
Status: Enrolling
Description: This study is testing the safety and tolerability of nebulized BX004-A, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (PsA) to find the best dose.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 40% or greater
Number of Visits: 11
Length of Participation: 189 days
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT05010577